MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (?)
Ratings Breakdown: 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $14.11 (219.26% upside)

Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
DateFirmActionRatingPrice TargetActions
6/7/2016Cowen and CompanyReiterated RatingOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016WedbushReiterated RatingNeutral$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Jefferies GroupReiterated RatingHold$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Roth CapitalReiterated RatingBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Brean CapitalReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016HC WainwrightLower Price TargetBuy$25.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016OppenheimerDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016GuggenheimDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Cantor FitzgeraldLower Price TargetBuy$31.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015WBB SecuritiesReiterated RatingBuy$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Celldex Therapeutics (NASDAQ:CLDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3($0.35)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.34)($0.33)$2.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q3($0.31)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.32)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014($0.25)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.39)($0.34)($0.36)
Q2 20167($0.39)($0.29)($0.34)
Q3 20167($0.38)($0.27)($0.32)
Q4 20167($0.39)($0.20)($0.31)
(Data provided by Zacks Investment Research)
Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Celldex Therapeutics (NASDAQ:CLDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Celldex Therapeutics (NASDAQ:CLDX)
DateHeadline
06/29/16 08:19 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Performance and Session Recap - Engelwood Daily
06/29/16 08:19 PMCurrent Analysts Rating Update: Astrazeneca PLC (NYSE:AZN) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates
06/28/16 08:21 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX): Reviewing Stock Performance - Press Telegraph
06/28/16 08:21 PMFocus Stock Recap for: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Telanagana Press
06/28/16 08:06 AMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Broker Price Targets For The Coming Week - Fiscal Standard
06/28/16 07:25 AMCelldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : June 28, 2016 -
06/27/16 03:13 PMEquity Research and Technical Review on Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
06/27/16 03:13 PMWatching Stock Sentiment for:Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
06/23/16 04:42 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX): Share Update and Performance Review - Press Telegraph
06/22/16 08:30 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Momentum at Critical Inflection Point - CML News
06/16/16 03:15 PMNotable Earnings Analysis: W&T Offshore Inc. (NYSE:WTI), Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Beacon Chronicle
06/16/16 07:38 AMAnalysts Tips to Monitor: Boston Scientific Corporation (NYSE:BSX) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates
06/16/16 07:38 AMEarnings Estimates Spotlight: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - News Oracle
06/15/16 03:21 PMRecently Issued Stock Ratings For Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Fiscal Standard
06/15/16 07:03 AM4 Cancer Drug Developers You Need to Have on Your Radar This Year -
06/14/16 03:10 PMAnalyst Recommended Stock: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - News Oracle
06/14/16 03:10 PMPrice Target Summary: Celldex Therapeutics, Inc. (NASDAQ:CLDX), SM Energy Company (NYSE:SM) - Beacon Chronicle
06/14/16 07:32 AMUpdated Analysts Rating Report: Mylan N.V. (NASDAQ:MYL) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates
06/13/16 11:13 AMAnalyst's Noticeable Buzzers: Zoetis Inc. (NYSE:ZTS) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates
06/13/16 11:13 AMAnalyst Best Overview on These Stocks: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Juniper Networks, Inc. (NYSE ... - Beacon Chronicle
06/13/16 07:16 AMCelldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : June 13, 2016 -
06/11/16 03:20 PMInvestor Catching Stock: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - News Oracle
06/11/16 03:20 PMCelldex Therapeutics Inc. (CLDX) Drops 8.47% on June 09 - Equities.com
06/11/16 11:29 AMCelldex Therapeutics Inc. (CLDX) Drops 8.47% on June 09
06/10/16 03:20 PMCan Celldex Therapeutics, Inc. (NASDAQ:CLDX) Keep Up with Analyst Expectations? - Investor Newswire
06/09/16 03:13 PMEarnings Trend per share for Investors: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Leucadia National Corporation ... - Beacon Chronicle
06/09/16 09:38 AMCELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 09:42 PMWhy Celldex Therapeutics, Inc. Stock Rose 14.5% in May - Motley Fool
06/08/16 03:48 PMAnalyst Buzz: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - News Oracle
06/08/16 12:05 PMCelldex Rose on Phase 2 Melanoma Data -
06/08/16 11:46 AMAnalysts Actions to Track: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates
06/08/16 11:46 AMCELLDEX THERAPEUTICS INC. (NASDAQ:CLDX) Financial Condition Compared to S&P 500 - CML News
06/07/16 08:52 PMCelldex Therapeutics Inc. (CLDX) Jumps 6.58% on June 06 - Equities.com
06/07/16 03:13 PMAnalyst Ratings Buzz: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - News Oracle
06/07/16 03:13 PMWhat's Celldex Therapeutics, Inc. (NASDAQ:CLDX) Brewing In Its Pipeline? - Market Exclusive
06/07/16 02:04 PMWhy Celldex Therapeutics, Inc. Stock Rose 14.5% in May -
06/06/16 08:42 PMAnalyst Opinion of: Celldex Therapeutics (CLDX) - News Oracle
06/06/16 03:06 PMNotable Earnings Analysis: CSX Corp. (NASDAQ:CSX), Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Beacon Chronicle
06/06/16 03:06 PMCelldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock - TheStreet.com
06/06/16 06:56 AMHC Stocks Judgment: Bristol-Myers Squibb Co (NYSE:BMY), Celldex Therapeutics, Inc. (NASDAQ:CLDX) - share market updates (press release)
06/05/16 07:47 PM8:47 pm Celldex Therapeutics presents data establishing CDX301's utility as a dendritic cell growth factor in combination therapy -
06/04/16 08:37 PMCelldex Therapeutics' CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients ... - GlobeNewswire (press release)
06/04/16 01:18 PMCelldex Therapeutics' CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma - [at noodls] - June 4, 2016 HAMPTON, N.J., June 04, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today results from a Phase 2 clinical study evaluating CDX‑1401 and CDX‑301 in patients ...
06/04/16 01:02 PMCelldex Therapeutics’ CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma - [GlobeNewswire] - HAMPTON, N.J., June 04, 2016-- Celldex Therapeutics, Inc. announced today results from a Phase 2 clinical study evaluating CDX‑ 1401 and CDX‑ 301 in patients with malignant melanoma, which was conducted ...
06/03/16 09:20 PMCelldex Therapeutics (CLDX): Today's Weak On High Volume Stock - TheStreet.com
06/03/16 03:22 PMEarnings Report of the Stocks: NRG Energy, Inc. (NYSE:NRG), Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Beacon Chronicle
06/03/16 11:51 AMSentiment Score Update: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - HNN
06/03/16 11:51 AMCelldex Therapeutics Inc. (CLDX) Jumps 9.89% on June 02 - Equities.com
06/02/16 03:22 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Near Term Target Update - Stock Tick Tock - Celldex Therapeutics, Inc. (NASDAQ:CLDX) Near Term Target UpdateStock Tick TockSell-siders covering shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have a consensus price target of $8.625 for the next 12-18 months. Analysts study the companies they cover in order to present the sell-side institutions with the information ...and more »
06/02/16 03:22 PMTarget Price Outlook on Celldex Therapeutics, Inc. (NASDAQ:CLDX) - HNN - Target Price Outlook on Celldex Therapeutics, Inc. (NASDAQ:CLDX)HNNEquity analysts that track Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares have provided targets on where they believe the stock will move in the future. The present consensus target price compiled using analysts polled by Zacks Research sits at $8.625.and more »
About Celldex Therapeutics

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CLDX
  • CUSIP: 15117B10
Key Metrics:
  • Previous Close: $4.42
  • 50 Day Moving Average: $4.26
  • 200 Day Moving Average: $6.76
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $436.33M
  • Current Quarter EPS Consensus Estimate: $-1.34 EPS
Additional Links:
Celldex Therapeutics (NASDAQ:CLDX) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha